Bernd Jilma Selected Research

ARC 1779

8/2012	The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
4/2012	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
9/2011	A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
3/2011	Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
9/2010	A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
5/2010	The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
10/2009	Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
8/2009	The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernd Jilma Research Topics

Disease

43	Inflammation (Inflammations) 04/2022 - 02/2002
37	Endotoxemia 01/2022 - 05/2002
30	Hemorrhage 01/2022 - 12/2003
21	Thrombosis (Thrombus) 04/2022 - 11/2002
19	Myocardial Infarction 06/2022 - 09/2004
19	Sepsis (Septicemia) 01/2020 - 10/2002
17	Acute Coronary Syndrome 01/2022 - 10/2002
13	Stroke (Strokes) 01/2021 - 04/2003
12	Cardiovascular Diseases (Cardiovascular Disease) 12/2020 - 10/2003
11	COVID-19 01/2022 - 10/2020
10	Disseminated Intravascular Coagulation 01/2022 - 05/2002
10	Infections 07/2016 - 02/2006
9	Autoimmune Hemolytic Anemia (Cold Agglutinin Disease) 01/2022 - 01/2019
9	Atherosclerosis 12/2020 - 09/2004
8	ST Elevation Myocardial Infarction 04/2022 - 06/2010
8	Heart Arrest (Cardiac Arrest) 02/2022 - 03/2009
8	Critical Illness (Critically Ill) 01/2020 - 10/2002
8	Coronary Artery Disease (Coronary Atherosclerosis) 01/2017 - 01/2006
7	Neoplasms (Cancer) 01/2020 - 02/2006
7	Chronic Hepatitis C 01/2020 - 02/2006
7	Thrombocytopenia (Thrombopenia) 07/2016 - 10/2002
6	Ischemic Stroke 06/2022 - 09/2004
6	Mastocytosis 01/2022 - 01/2019
6	Anaphylaxis (Anaphylactic Shock) 01/2022 - 01/2019
6	Hemolysis 01/2022 - 02/2003
6	Out-of-Hospital Cardiac Arrest 09/2021 - 10/2018
6	Thrombotic Thrombocytopenic Purpura 04/2015 - 10/2009
5	Unstable Angina 01/2022 - 03/2005
5	Birth Weight (Birth Weights) 01/2020 - 07/2006
4	Body Weight (Weight, Body) 01/2022 - 01/2009
4	Heart Failure 11/2021 - 11/2019
4	Septic Shock (Toxic Shock Syndrome) 10/2020 - 12/2015
4	Bacteremia 01/2020 - 10/2002
3	Hypothermia 02/2022 - 07/2009
3	Type 2 von Willebrand Disease 01/2022 - 09/2010
3	Diabetes Mellitus 01/2021 - 07/2013
3	Venous Thromboembolism 01/2020 - 08/2006
3	Necrosis 07/2018 - 02/2007

Drug/Important Bio-Agent (IBA)

24	von Willebrand FactorIBA 01/2022 - 04/2004
15	TicagrelorIBA 01/2022 - 11/2010
14	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 04/2003
13	CytokinesIBA 01/2022 - 11/2002
13	C-Reactive ProteinIBA 09/2021 - 10/2006
13	Clopidogrel (Plavix)FDA Link 11/2020 - 04/2003
13	Thromboplastin (Tissue Factor)IBA 01/2020 - 05/2002
13	EndotoxinsIBA 05/2018 - 02/2002
12	Interleukin-6 (Interleukin 6)IBA 11/2021 - 01/2004
11	Pharmaceutical PreparationsIBA 02/2022 - 09/2003
11	Thrombin FDA Link 01/2020 - 09/2003
10	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2004
10	AnticoagulantsIBA 01/2022 - 05/2002
10	fibrin fragment D (D-dimer)IBA 12/2021 - 05/2002
10	VaccinesIBA 08/2021 - 11/2008
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2002
8	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2011
8	ARC 1779IBA 08/2012 - 08/2009
7	Histamine (Histamine Dihydrochloride)FDA Link 04/2022 - 12/2015
7	sutimlimabIBA 01/2022 - 01/2019
7	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 01/2003
7	Adenosine Diphosphate (ADP)IBA 01/2018 - 09/2004
6	Hemoglobins (Hemoglobin)IBA 01/2022 - 10/2006
6	EnzymesIBA 01/2022 - 11/2008
6	Prasugrel Hydrochloride FDA Link 01/2021 - 11/2012
6	FibrinIBA 01/2021 - 05/2002
6	AntigensIBA 01/2020 - 02/2006
6	CollagenIBA 01/2020 - 09/2004
6	thiamine triphosphorate (TTP)IBA 02/2016 - 10/2009
5	Morphine (MS Contin)FDA LinkGeneric 01/2022 - 02/2014
5	Heparin (Liquaemin)FDA LinkGeneric 01/2022 - 10/2002
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021 - 02/2002
5	AntibodiesIBA 11/2021 - 06/2006
5	Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric 07/2020 - 03/2005
5	Fibrinogen (Factor I)FDA Link 02/2018 - 01/2007
5	Messenger RNA (mRNA)IBA 03/2017 - 09/2003
5	Glycoproteins (Glycoprotein)IBA 11/2016 - 02/2003
5	LipopolysaccharidesIBA 03/2009 - 02/2002
4	Amine Oxidase (Copper-Containing)IBA 04/2022 - 01/2018
4	BilirubinIBA 01/2021 - 02/2018
4	TabletsIBA 01/2021 - 01/2015
4	Complement System Proteins (Complement)IBA 01/2021 - 01/2019
4	Platelet Membrane Glycoprotein IIbIBA 11/2016 - 12/2003
3	Platelet Membrane GlycoproteinsIBA 01/2022 - 01/2020
3	Complement C1s (C1 Esterase)IBA 01/2022 - 01/2019
3	Erythropoietin FDA Link 01/2021 - 07/2006
3	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2021 - 01/2020
3	Prothrombin (Factor II)IBA 10/2020 - 10/2006
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2020 - 02/2010
3	Protein CIBA 06/2019 - 09/2003
3	P-SelectinIBA 07/2018 - 02/2003
3	vasodilator-stimulated phosphoproteinIBA 01/2018 - 11/2008
3	Purinergic P2Y Receptor AntagonistsIBA 11/2016 - 07/2013

Therapy/Procedure

26	Therapeutics 01/2021 - 10/2002
9	Percutaneous Coronary Intervention 12/2020 - 03/2005
6	Stents 04/2022 - 07/2013
5	Induced Hypothermia 02/2022 - 07/2009
4	Heart-Assist Devices 11/2019 - 01/2009
3	Critical Care (Surgical Intensive Care) 02/2022 - 05/2016
3	Length of Stay 10/2021 - 12/2012
3	Subcutaneous Injections 08/2021 - 01/2020
3	Electrodes (Electrode) 01/2017 - 09/2013